natgillin/translations-raw huggingface dataset:
Some fatalities have occurred, primarily with mixed overdoses, but also with duloxetine alone at a dose of approximately 1000 mg. Signs and symptoms of overdose (duloxetine alone or in combination with other medicinal products) included somnolence, coma, serotonin syndrome, seizures, vomiting and tachycardia. 
Znakovi i simptomi predoziranja (samim duloksetinom ili u kombinaciji s drugim lijekovima) uključivali su somnolenciju,
Eructation Gastritis Dysphagia Flatulence Breath odour 
Poremećaji probavnog sustava mučnina suha usta konstipacija proljev bol u abdomenu povraćanje dispepsija gastrointestinalno krvarenje7 gastroenteritis stomatitis podrigivanje gastritis disfagija flatulencija zadah iz usta
Hypertension3,7 Flushing 
Krvožilni poremećaji hipertenzija3,7 crvenilo uz osjećaj vrućine sinkopa2 povišeni krvni tlak3
• dizziness, tingling feelings like pins and needles or electric shock-like feelings (particularly in the head), sleep disturbances (vivid dreams, nightmares, inability to sleep), fatigue, sleepiness, feeling restless or agitated, feeling anxious, feeling sick (nausea) or being sick (vomiting), shaking (tremor), headaches, muscle pain, feeling irritable, diarrhoea, excessive sweating or vertigo. 
poremećaji spavanja (živopisni snovi, noćne more, nemogućnost spavanja), umor, pospanost, osjećaj nemira ili uznemirenosti, osjećaj tjeskobe, mučnina ili povraćanje, nevoljno drhtanje
Blurred vision Mydriasis Visual impairment 
Poremećaji oka zamućen vid midrijaza poremećaj vida suho oko glaukom
Clinical efficacy and safety 
UČINKOVITU PRIMJENU LIJEKA
• muscle twitching 
• trzanje mišića
• feeling sick (nausea), dry mouth, constipation • fatigue 
• mučnina, suha usta, zatvor
• throat tightness, nose bleeds 
• stezanje u grlu, krvarenja iz nosa
YENTREVE 20 mg hard gastro-resistant capsules. 
(20 mg tvrde želučanootporne kapsule)
Tremor 
OBLIK
YENTREVE 40 mg hard gastro-resistant capsules. 
KUTIJE ZA 40 MG TVRDE ŽELUČANOOTPORNE KAPSULE
Sugar spheres 
Gospina trava
Duloxetine is very weakly excreted into human milk based on a study of 6 lactating patients, who did not breast feed their children. 
Na temelju ispitivanja provedenom na 6 bolesnica u laktaciji koje nisu dojile svoju djecu pokazalo se da se duloksetin u majčino mlijeko izlučuje u vrlo maloj mjeri.
YENTREVE 40 mg hard gastro-resistant capsules YENTREVE 20 mg hard gastro-resistant capsules 
YENTREVE 40 mg tvrde želučanootporne kapsule YENTREVE 20 mg tvrde želučanootporne kapsule duloksetin (u obliku duloksetinklorida)
Eli Lilly Ges.m.b.H. 
Eli Lilly Norge A.S
Feeling hot 
periferna hladnoća
If you get any side effects, talk to your doctor of pharmacist. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
Dyskinesia Restless legs syndrome 
Antibiotik linezolid je reverzibilan neselektivan MAO
Gynaecological haemorrhage Menopausal symptoms 
Poremećaji reproduktivnog sustava i dojki ginekološko krvarenje simptomi menopauze menstrualni poremećaj galaktoreja hiperprolaktinemija poslijeporođajno krvarenje6
Haemorrhage 
• umor
Respiratory, thoracic and mediastinal disorders Yawning 
poput ekhimoza, purpure i gastrointestinalnih krvarenja.
Very rare 
Vrlo rijetko:
EMA/PRAC/590265/2015 
EMA/PRAC/618057/2015 Corr1
What you need to know before you <take> <use> X: 
Dio 2: Što morate znati prije nego počnete <uzimati> <primjenjivati> X
Adopted at the 7-10 September 2015 PRAC 
Usvojeno na sjednici PRAC-a 7. - 10. rujna 2015.
• Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
• Obratite se liječniku ako imate bol u uhu, iscjedak iz uha i/ili infekciju uha.
Section 4.4 
Dio 4.4:
Possible side effects Tell your doctor immediately if you experience: 
Dio 4.: Moguće nuspojave Odmah obavijestite svog liječniku u slučaju:
Frequency ‘not known': pulmonary hypertension 
Učestalost „nepoznato": plućna hipertenzija
Bisphosphonates (alendronic acid; alendronic acid, colecalciferol; clodronic acid; etidronic acid; ibandronic; neridronic acid; pamidronic acid; risedronic acid; tiludronic acid; zoledronic acid) - Osteonecrosis of the external auditory canal (EPITT no 18256) 
Bisfosfonati (alendronatna kiselina; alendronatna kiselina, kolekalciferol; klodronatna kiselina; etidronatna kiselina; ibandronatna kiselina; neridronatna kiselina; pamidronatna kiselina; risedronatna kiselina; tiludronatna kiselina; zoledronatna kiselina) - osteonekroza vanjskog slušnog kanala (EPITT br. 18256)
HLA-DRB1*04:03 allele (susceptibility to IAS odds ratio: 1.6) is especially found in Caucasians, with a higher prevalence in southern than in northern Europe and HLA-DRB1*04:06 allele (susceptibility to IAS odds ratio: 56.6) is especially found in Japanese and Korean patients. 
HLA-DRB1*04:03 alel (omjer izgleda podložnosti prema IAS: 1,6) posebno je prisutan u bijelaca, s većom prevalencijom na jugu u odnosu na sjever Europe i HLA-DRB1*04:06 alel (omjer izgleda podložnosti prema IAS: 56,6) posebno je prisutan u japanskih i korejskih bolesnika.
Leflunomide - Pulmonary hypertension (EPITT no 18221) 
Leflunomid1 - plućna hipertenzija (EPITT br. 18221)
- a cough or breathing problems as these may indicate inflammation problems of the lung (interstitial lung disease or pulmonary hypertension); 
- kašlja ili problema s disanjem, jer to može upućivati na upalu probleme s plućima (intersticijska plućna bolest ili plućna hipertenzija),
Frequency ‘uncommon': Cases of suspected capillary leak syndrome have been reported with trabectedin. 
Učestalost „manje često": Slučajevi sumnje na sindrom kapilarnog curenja prijavljeni su s trabektedinom.
IAS should be considered in the differential diagnosis of spontaneous hypoglycaemia in patients using thioctic acid (see section 4.8). 
IAS je potrebno uzeti u obzir u diferencijalnoj dijagnozi spontane hipoglikemije u bolesnika koji koriste tioktatnu kiselinu (vidjeti dio 4.8.).
Patients with a certain human leukocyte antigen genotype (which is more frequent in Japanese and Korean patients, but is also found in Caucasians) are more prone to development of insulin autoimmune syndrome (disorder of the blood glucose regulating hormones with pronounced lowering of blood sugar levels) when treated with thioctic acid. 
Bolesnisi s određenim genotipom humanog leukocitnog antigena (koji je češće prisutan u japanskih i korejskih bolesnika, no prisutan je i u bijelaca) podložniji su razvitku autoimunog inzulinskog sindroma (poremećaj hormona koji reguliraju glukozu u krvi sa značajnim sniženjem koncentracije šećera u krvi) kada se liječe tioktatnom kiselinom.
Cases of Insulin Autoimmune Syndrome (IAS) have been reported during treatment with thioctic acid. 
Insulin Autoimmune Syndrome, IAS) prijavljeni su tijekom liječenja tioktatnom kiselinom.
The risk of its their occurrence is can be increased in patients with a history of interstitial lung disease. 
Rizik od njezine njihove pojave može biti povećan je u bolesnika s intersticijskom plućnom bolesti u anamnezi.
Patients with human leukocyte antigen genotype such as HLA-DRB1*04:06 and HLA-DRB1*04:03 alleles, are more susceptible to develop IAS when treated with thioctic acid. 
Bolesnici s genotipom humanog leukocitnog antigena poput HLA-DRB1*04:06 i HLA-DRB1*04:03 alela, podložniji su razvitku IAS-a kada se liječe tioktatnom kiselinom.
Section 4.8 Very rare: Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction). 
Vrlo rijetko: Osteonekroza vanjskog slušnog kanala (nuspojava razreda bisfosfonata).
Frequency unknown: Disorder of the blood glucose regulating hormones with pronounced lowering of blood sugar levels (insulin autoimmune syndrome). 
Nepoznata učestalost: Poremećaj hormona koji reguliraju glukozu u krvi sa značajnim sniženjem koncentracije šećera u krvi (autoimuni inzulinski sindrom).
Interstitial lung disease, as well as rare cases of pulmonary hypertension has have been reported during treatment with leflunomide (see section 4.8). 
Za vrijeme liječenja leflunomidom zabilježena je intersticijska plućna bolest, kao i rijetki slučajevi plućne hipertenzije (vidjeti dio 4.8.).
Frequency unknown: insulin autoimmune syndrome (see section 4.4) 
Učestalost nije poznata: autoimuni inzulinski sindrom (vidjeti dio 4.4.).
Other side effects such as kidney failure, a decrease in the levels of uric acid in your blood, pulmonary hypertension, male infertility [...] may also occur with an unknown frequency. 
Također se mogu javiti druge nuspojave, poput zatajenja bubrega, smanjene koncentracije mokraćne kiseline u krvi, plućne hipertenzije, muške neplodnosti [...], ali je njihova učestalost nepoznata.
Trabectedin - Capillary leak syndrome (EPITT no 18115) 
Trabektedin - Sindrom kapilarnog curenja (EPITT br.
Section 4.8 - Undesirable effects: Respiratory, thoracic and mediastinal disorders 
Dio 4.4 - Posebna upozorenja i mjere opreza pri uporabi
Thioctic acid - Insulin autoimmune syndrome (EPITT no 
Tioktatna kiselina - autoimuni inzulinski sindrom (EPITT br. 18406)
The way it works in this disease is not completely understood. 
Način djelovanja kod ove bolesti nije u potpunosti poznat.
As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 10 August 2010. 
Budući da je tvrtka dostavila dodatne zatražene informacije, „iznimne okolnosti” prestale su vrijediti 10. kolovoza
This summary was last updated in 11-2016. 
Sažetak je posljednji put ažuriran: 11.2016.
The infusion should last one to two hours, but it may last longer if the patient has certain side effects. 
Infuzija treba trajati jedan do dva sata, ali može trajati dulje ako bolesnik ima određene nuspojave.
If this does not happen by day 50 (for previously treated patients) or by day 60 (for newly diagnosed patients), the treatment should be stopped. 
Ako se to ne dogodi do 50. dana (u prethodno liječenih bolesnika) ili do 60. dana (u novodijagnosticiranih bolesnika), liječenje se treba prekinuti.
The full EPAR for Trisenox can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Trisenox nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Forty-five of the patients in the studies were adults. 
Četrdeset i pet bolesnika u ispitivanjima bili su odrasle osobe.
The main measure of effectiveness was the number of patients who had complete remission. 
Glavna mjera djelotvornosti bio je broj bolesnika s potpunom remisijom.
On average, it took 57 days for the patients to reach complete remission. 
Bolesnicima je u prosjeku trebalo 57 dana za postizanje potpune remisije.
The treatment is divided into 2 phases: induction and consolidation. 
Liječenje je podijeljeno u dvije faze: fazu indukcije i fazu konsolidacije.
Trisenox was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval. 
Lijek Trisenox prvobitno je odobren u „iznimnim okolnostima” zbog toga što su, uzevši u obzir da je bolest rijetka, u trenutku izdavanja odobrenja bile dostupne samo ograničene informacije.
The number of times these cycles are repeated depends on whether patients have received previous treatment or not. 
Broj ponavljanja ciklusa ovisi o tome jesu li bolesnici prethodno liječeni.
The European Commission granted a marketing authorisation valid throughout the European Union for Trisenox on 5 March 2002. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Trisenox na snazi u Europskoj uniji od 5. ožujka 2002.
The most common side effects with Trisenox (seen in 1 patient in 10) are hyperglycaemia (high blood glucose levels), hypomagnesaemia (low blood magnesium levels), hypokalaemia (low blood potassium levels), paraesthesia (unusual sensations like pins and needles), dizziness, headache, tachycardia (rapid heartbeat), dyspnoea (difficulty breathing), differentiation syndrome (a potentially fatal complication of chemotherapy in patients with APL), diarrhoea, vomiting, nausea (feeling sick), pruritus (itching), rash, myalgia (muscle pain), pyrexia (fever), pain, fatigue (tiredness), oedema (swelling), prolonged QT interval on an electrocardiogram (an alteration of the electrical activity of the heart), and increased levels of alanine aminotransferase and aspartate aminotransferase (liver enzymes). 
Najčešće nuspojave lijeka Trisenox (uočene u 1 na 10 bolesnika) jesu hiperglikemija (povišena razina glukoze u krvi), hipomagnezijemija (niske razine magnezija u krvi), hipokalemija (niske razine kalija u krvi), parestezija (neuobičajeni osjeti poput bockanja iglama), omaglica, glavobolja, tahikardija (ubrzani otkucaji srca), dispneja (poteškoće u disanju), sindrom diferencijacije (potencijalno smrtonosna komplikacija kemoterapije u bolesnika s APL-om), proljev, povraćanje, mučnina, pruritus (svrbež), osip, mialgija (bol u mišićima), pireksija (vrućica), bol, umor (malaksalost), edem (oticanje), produljeni QT interval na elektrokardiogramu (promjena električne aktivnosti srca) i povišene razine alanin aminotransferaze i aspartat aminotransferaze (jetreni enzimi).
This is a summary of the European public assessment report (EPAR) for Trisenox. 
Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) za lijek Trisenox.
Looking at the results of these two studies together, 87% of the patients had complete remission (45 out of 52). 
Uzevši u obzir rezultate obaju ispitivanja zajedno, u 87 % bolesnika (45 od 52) zabilježena je potpuna remisija.
During the consolidation phase, Trisenox is given once a day for five days, followed by a two-day break, repeated for four or five weeks. 
Tijekom faze konsolidacije lijek Trisenox daje se jedanput dnevno tijekom pet dana nakon čega slijedi pauza od dva dana, a cijeli se postupak ponavlja četiri ili pet tjedana.
• Patients with APL whose disease has not responded to previous treatment with a retinoid and cancer medicines, or when their disease has come back after this type of treatment. 
• u bolesnika s APL-om čija bolest nije reagirala na prethodno liječenje retinoidnim lijekovima i lijekovima za liječenje raka ili čija se bolest ponovno javila nakon takvog liječenja.
97% (72 out of 74) of patients treated with Trisenox did not have any event, compared with 86% (65 out of 76) of those treated with anthracyclines. 
U 97 % bolesnika (72 od 74) liječenih lijekom Trisenox nije zabilježen nikakav događaj, u usporedbi s 86 % bolesnika (65 od 76) liječenih antraciklinima.
It is thought to prevent the production of DNA, which is necessary for leukaemia cells to grow. 
Smatra se da sprečava stvaranje DNK koja je neophodna za rast stanica leukemije.
The recommended dose of Trisenox depends on the body weight of the patient. 
Preporučena doza lijeka Trisenox ovisi o tjelesnoj težini bolesnika.
What measures are being taken to ensure the safe and effective use of Trisenox? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Trisenox?
The translocation affects the way the white blood cells grow, and as a result they lack the ability to use retinoic acid (vitamin A). 
Translokacija utječe na rast bijelih krvnih stanica, koje kao rezultat toga nisu sposobne upotrebljavati retinoatnu kiselinu (vitamin A).
During the induction phase, Trisenox is given every day until there are signs that the treatment is working (when the bone marrow does not contain any leukaemia cells). 
Tijekom faze indukcije lijek Trisenox daje se svakog dana do pojave znakova da liječenje djeluje (kada u koštanoj srži nema stanica leukemije).
It is not intended to provide practical advice on how to use Trisenox. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Trisenox.
Why is Trisenox approved? 
Zašto je Trisenox odobren?
This is when there are no more leukaemia cells in the bone marrow and the levels of platelets and white blood cells in the blood have recovered. 
To je stanje kada u koštanoj srži više nema stanica leukemije, a razine trombocita i bijelih krvnih stanica vraćene su na uobičajene razine.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trisenox have been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Trisenox nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
What is Trisenox and what is it used for? 
Što je Trisenox i za što se koristi?
Other information about Trisenox 
Ostale informacije o lijeku Trisenox
The CHMP decided that Trisenox's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za lijekove za primjenu kod ljudi odlučio je da koristi lijeka Trisenox nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
Trisenox is used to treat adults (aged 18 years or over) with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic ‘translocation' (when there is a swap of genes between two chromosomes). 
Lijek Trisenox primjenjuje se u liječenju odraslih osoba (u dobi od 18 godina ili više) s akutnom promijelocitnom leukemijom (APL), rijetkim oblikom leukemije (rak bijelih krvnih stanica) izazvanom translokacijom gena (zamjena gena između dvaju kromosoma).
Trisenox has also been investigated in two studies involving a total of 52 patients with APL who had been previously treated with an anthracycline and a retinoid. 
Lijek Trisenox također je ispitivan u dvama ispitivanjima koja su obuhvatila ukupno 52 bolesnika s APL-om koji su prethodno liječeni antraciklinom i retinoidom.
Patients with APL are normally treated with retinoids (substances derived from vitamin A). 
Bolesnici s APL-om uglavnom se liječe retinoidima (derivati vitamina A).
Trisenox can only be obtained with a prescription and treatment should be supervised by a doctor who has experience in the management of patients with acute leukaemias. 
Lijek Trisenox izdaje se samo na recept, a liječenje mora nadzirati liječnik s iskustvom u liječenju bolesnika s akutnim leukemijama.
What are the risks associated with Trisenox? 
Koji su rizici povezani s lijekom Trisenox?
• Patients with newly diagnosed low or intermediate risk APL where it is used together with the medicine all-trans-retinoic acid (ATRA). 
• u bolesnika s novodijagnosticiranim APL-om niskog do srednjeg rizika u kombinaciji sa svetrans-retinoatnom kiselinom (ATRA);
For more information about treatment with Trisenox, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o liječenju lijekom Trisenox pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
Trisenox was not compared with any other medicine in either study. 
Ni u jednom ispitivanju Lijek Trisenox nije uspoređivan s drugim lijekom.
The active substance in Trisenox, arsenic trioxide, is a chemical that has been used in medicines for many years, including for the treatment of leukaemia. 
Djelatna tvar u lijeku Trisenox, arsenov trioksid, kemijski je spoj koji se niz godina upotrebljava u lijekovima, među ostalim za liječenje leukemije.
Trisenox arsenic trioxide 
Trisenox arsenov trioksid
Trisenox is used in: 
Lijek Trisenox primjenjuje se:
For practical information about using Trisenox, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Trisenox bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
What benefits of Trisenox have been shown in studies? 
Koje su koristi lijeka Trisenox dokazane u ispitivanjima?
How does Trisenox work? 
Kako djeluje Trisenox?
Trisenox contains the active substance arsenic trioxide. 
Lijek Trisenox sadrži djelatnu tvar arsenov trioksid.
For the full list of all side effects and restrictions with Trisenox, see the package leaflet. 
Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Trisenox potražite u uputi o lijeku.
How is Trisenox used? 
Kako se Trisenox koristi?
Trisenox has been investigated in 159 newly diagnosed patients who had not yet received any treatment for APL. Trisenox was compared with an anthracycline (a type of cancer medicine), both taken in combination with ATRA, and the measure of effectiveness was the number of patients who did not experience any event (such as worsening of their disease or death) 2 years after diagnosis. 
Oba su lijeka bila uzimana u kombinaciji s ATRA-om, a mjera djelotvornosti bio je broj bolesnika kod kojih dvije godine nakon dijagnoze nije došlo do nikakvih događaja (pogoršanja bolesti ili smrti).
Centaury should only be used in adults and elderly. 
Kičicina zelen se smije koristiti samo u odraslih i starijih osoba.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom2. veljače 2016.
Studies in laboratory tests indicate an effect as appetite and digestion stimulant, although the data available are very limited. 
Ispitivanja provedena u laboratoriju kao učinak naznačuju stimulaciju apetita i probave, iako su dostupni podatci vrlo ograničeni.
If symptoms last longer than 2 weeks during use of the medicine, a doctor or a qualified healthcare practitioner should be consulted. 
Ako simptomi tijekom primjene traju dulje od 2 tjedna, potrebno se obratiti liječniku ili kvalificiranom zdravstvenom radniku.
In some cases the solvent is partially evaporated to obtain a soft extract. 
U nekim se slučajevima otapalo djelomično isparava kako bi se dobio meki ekstrakt.
What are the HMPC conclusions on its medicinal uses? 
Koji su zaključci HMPC-a o njezinoj medicinskoj primjeni?
Centaury medicines should not be taken by people with ulcers in the stomach. 
Lijekove koji sadrže kičicinu zelen ne bi trebali uzimati ljudi s čirom na želucu.
At the time of the HMPC assessment, no side effects had been reported with these medicines. 
U vrijeme kad je HPMC procjenjivao lijek, nisu prijavljene nikakve nuspojave prilikom primjene ovih lijekova.
This summary is not intended to provide practical advice on how to use medicines containing centaury. 
Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže kičicinu zelen.
What is centaury? 
Što je kičicina zelen?
For detailed information on the studies assessed by the HMPC, see the HMPC assessment report. 
Za detaljnije informacije o ispitivanjima koje je procijenio HMPC pogledajte izvješće HMPC-a o procjeni lijeka.
Any applications for the licensing of medicines containing centaury have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Svi zahtjevi za odobrenje lijekova koji sadrže kičicinu zelen moraju se podnijeti nacionalnim tijelima nadležnima za lijekove koja procjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
Further information on the risks associated with centaury medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Više o rizicima povezanim s lijekovima koji sadrže kičicinu zelen, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
Further information on the HMPC assessment of centaury medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Daljnje informacije o HMPC-ovoj procjeni lijekova koji sadrže kičicinu zelen, uključujući pojedinosti zaključaka Odbora, nalaze se pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.